No connection

Search Results

CON vs PRVA

CON
Concentra Group Holdings Parent, Inc.
NEUTRAL
Price
$22.82
Market Cap
$2.93B
Sector
Healthcare
AI Confidence
80%
PRVA
Privia Health Group, Inc.
NEUTRAL
Price
$24.02
Market Cap
$3.02B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
CON
17.55
PRVA
126.42
Forward P/E
CON
13.73
PRVA
20.08
P/B Ratio
CON
7.46
PRVA
4.03
P/S Ratio
CON
1.36
PRVA
1.42
EV/EBITDA
CON
11.84
PRVA
57.87

Profitability

Gross Margin
CON
28.34%
PRVA
9.87%
Operating Margin
CON
13.24%
PRVA
2.08%
Profit Margin
CON
7.69%
PRVA
1.08%
ROE
CON
48.07%
PRVA
4.03%
ROA
CON
8.03%
PRVA
1.71%

Growth

Revenue Growth
CON
15.9%
PRVA
17.4%
Earnings Growth
CON
60.1%
PRVA
132.8%

Financial Health

Debt/Equity
CON
5.01
PRVA
0.01
Current Ratio
CON
1.14
PRVA
1.6
Quick Ratio
CON
1.0
PRVA
1.55

Dividends

Dividend Yield
CON
1.1%
PRVA
--
Payout Ratio
CON
19.23%
PRVA
0.0%

AI Verdict

CON NEUTRAL

Concentra Group Holdings presents a dichotomy between strong growth and precarious leverage. While the Piotroski F-Score of 4/9 indicates stable financial health, the extreme Debt/Equity ratio of 5.01 is a significant risk factor that likely inflates the impressive 48.07% ROE. The stock trades at a significant premium to its Graham Number ($9.46) but remains well below its growth-based intrinsic value ($38.35), suggesting a valuation gap that analysts believe will close, despite a currently bearish technical trend.

Strengths
Strong YoY earnings growth of 60.10%
Robust Return on Equity (ROE) of 48.07%
Reasonable Forward P/E of 13.73 compared to growth rates
Risks
Excessive leverage with a Debt/Equity ratio of 5.01
Bearish technical trend (0/100 score)
Significant gap between current price and defensive Graham Number ($9.46)
PRVA NEUTRAL

PRVA presents a stark contrast between fundamental value and growth expectations, anchored by a stable Piotroski F-Score of 4/9. While the company maintains an exceptionally clean balance sheet with near-zero debt, it trades at a massive premium compared to its Graham Number ($5.05) and Intrinsic Value ($5.61). Strong analyst conviction and impressive YoY earnings growth are currently offset by aggressive insider selling from the CEO and CFO and razor-thin profit margins. The stock is essentially a high-growth bet where the market is pricing in future earnings far beyond current deterministic valuations.

Strengths
Exceptionally low Debt/Equity ratio (0.01), indicating minimal financial leverage risk
Strong revenue growth (17.40% YoY) and explosive annual earnings growth (132.80%)
Consistent track record of beating earnings estimates (3 of last 4 quarters)
Risks
Extreme valuation gap: Current price ($24.02) is >4x the Graham Number ($5.05)
Very thin profitability margins (Profit Margin: 1.08%, Gross Margin: 9.87%)
Bearish insider sentiment with significant selling by the CEO and CFO

Compare Another Pair

CON vs PRVA: Head-to-Head Comparison

This page compares Concentra Group Holdings Parent, Inc. (CON) and Privia Health Group, Inc. (PRVA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile